[ Back ] [ Bottom ]
90_SJ0035
LRB9005666JSgcB
1 SENATE JOINT RESOLUTION
2 WHEREAS, The General Assembly recognizes that cancer
3 clinical trials are designed to compare the effectiveness of
4 the standard medical treatment with a new therapy that
5 researchers believe will prove more effective, based on
6 scientific evidence and that such research provides the
7 foundation for improved patient care and decreased health
8 care costs; and
9 WHEREAS, The General Assembly recognizes that cancer
10 clinical trials involve a rigorously developed clinical
11 protocol that includes goals, rationale and background,
12 criteria for patient selection, specific directions for
13 administering therapy and monitoring patients, definition of
14 quantitative measures for determining treatment response, and
15 methods for documenting and treating adverse reactions; and
16 WHEREAS, The General Assembly recognizes that virtually
17 every major breakthrough for current standard medical
18 treatment has been developed through the clinical trial
19 system; and
20 WHEREAS, It is the intent of the General Assembly to
21 determine how the costs associated with cancer clinical
22 trials compare with the costs of standard therapy; therefore
23 be it
24 RESOLVED, BY THE SENATE OF THE NINETIETH GENERAL ASSEMBLY
25 OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES
26 CONCURRING HEREIN, that a Cancer Clinical Trials Task Force
27 is created; and be it further
28 RESOLVED, That with the assistance of a scientifically
29 recognized research facility, the Cancer Clinical Trials Task
30 Force shall review the claims and billing data from a sample
31 of the most current data available for Phase I, II, III, and
-2- LRB9005666JSgcB
1 IV cancer trial and non-trial patients, including a sample of
2 patients having lung, breast, prostate, colon, and ovarian
3 cancer; and be it further
4 RESOLVED, That patient privacy and confidentiality of
5 medical records shall be maintained; and be it further
6 RESOLVED, That the Cancer Clinical Trials Task Force
7 shall submit a report identifying and explaining any
8 incremental cost to the insurance industry that results from
9 cancer patients' participation in valid cancer clinical
10 trials to the Governor and General Assembly not later than
11 February 1, 1999; and be it further
12 RESOLVED, That the Cancer Clinical Trials Task Force may
13 accept gifts, grants, and other funds from any public or
14 private source to finance its work; and be it further
15 RESOLVED, That on or before October 1, 1997, the
16 President of the Senate shall appoint 2 members of the Senate
17 to the Task Force, designating one member as co-chairperson,
18 the Minority Leader of the Senate shall appoint one member of
19 the Senate to the Task Force, the Speaker of the House of
20 Representatives shall appoint 2 members of the House to the
21 Task Force, designating one member as co-chairperson, and the
22 Minority Leader of the House of Representatives shall appoint
23 one member of the House to the Task Force; the Director of
24 Public Health, the Director of Insurance, and the Director of
25 Central Management or their respective designees shall serve
26 as ex-officio members of the Task Force; and the remainder of
27 the Task Force shall consist of 4 members of the public
28 appointed by the President of the Senate, 2 members of the
29 public appointed by the Minority Leader of the Senate, 4
30 members of the public appointed by the Speaker of the House
31 of Representatives, and 2 members of the public appointed by
32 the Minority Leader of the House of Representatives; and be
-3- LRB9005666JSgcB
1 it further
2 RESOLVED, That a copy of this resolution shall be
3 transmitted to the Directors of Public Health, Insurance, and
4 Central Management Services.
[ Top ]